Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Feb, 2020 | Pages:
250 | Publisher: Grand View Research
Industry: Biotechnology | Report Format: Electronic (PDF)
The global viral vectors & plasmid DNA manufacturing market size is expected to reach USD 1.1 billion by 2027, exhibiting a 14.52% CAGR, during the forecast period, according to a new report by Grand View Research, Inc. Currently, more than 700 cell and gene therapies are in clinical trials and vectors are used in nearly 70% of these therapies. As a result, demand for vectors has exceeded the supply rate. Thus, an increase in the number of advanced therapy-based discovery programs initiated by biotechnology and pharmaceutical companies is expected to drive investments in the market. Current production methods for viral vectors are considered tedious, as they are only applicable for scale-out but not for scale-up. Development of a proprietary CAP-GT technology-based cell suspension system by CEVEC Pharmaceuticals GmbH has effectively addressed the challenge of scaling-up by allowing easy handling and improved efficiency of cells. Considering growing opportunities in vector production, the Original Equipment Manufacturers (OEMs) are making focused efforts to gain a competitive advantage in the market. For example, the introduction of ready-to-run factory-in-a-box to accelerate the production of virus-based therapeutics by GE healthcare, as a solution to simplify and advance the manufacturing process. Further key findings from the report suggest: • With high usage, attributed to its ability of high titer production and capability to induce strong humoral and T cell responses in various research applications, adenovirus held the leading viral vectors and plasmid DNA manufacturing market share in terms of revenue, in 2019 • Lentivirus vector is anticipated to register the fastest CAGR over the forecast period. This can be attributed to constant growth in the lentivirus-based gene therapy pipeline program • Downstream processing held the dominant revenue share in 2019, owing to the fact that this process involves purification steps that account for the majority of the overall manufacturing cost. Employment of expensive equipment and requirement of trained personnel for product recovery has further driven revenue in the segment • Antisense and RNAi therapy production is estimated as the key application of vector manufacturing, resulting in the dominance of this segment over other applications • The high adoption rate of viruses for aptamers and oligonucleotide development in comparison to other applications has driven revenue in antisense and RNAi therapy segment • High usage of vectors for therapeutic production have contributed to the large revenue share of pharmaceutical and biopharmaceutical companies. The number of biotech companies employing vector for therapies production is anticipated to multiply over the forecast period • Presence of a substantial number of advanced therapy products in the pipeline targeting various cancer forms has accelerated revenue share of the cancer segment over the years • Given the high number of biotech entities in parts of U.S., such as in California and Massachusetts, North America has maintained its dominance in terms of revenue. In addition, the active participation of regulatory bodies in improving the regulatory scenario for the market launch of advanced therapies has facilitated the high usage of vectors in U.S. • Merck, Cobra Biologics, Novasep, and uniQure N.V., are some key participants that are geared towards capitalizing the untapped opportunities in the market
Table of Content
Chapter 1 Executive Summary
1.1 Market Snapshot
Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Formulation & Validation
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Robust pipeline for gene therapies and viral vector vaccines
3.1.1.2 Technological advancements in manufacturing vectors
3.1.1.3 Highly competitive market and various strategies undertaken by market entities
3.1.2 Market restraint analysis
3.1.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
3.1.3 Challenge analysis
3.1.3.1 Production capacity challenges
3.1.3.1 Manufacturing challenges pertaining to large-scale production of vectors
3.1.4 Opportunity analysis
3.1.4.1 Facility expansion for cell and gene therapies
3.2 Viral Vector Production: Stepwise Challenges & Solutions
3.2.1 Plasmid Production: Challenges & Solutions
3.2.2 Host Cell Production & Banking Needs
3.2.3 Viral Vector Production, F&F: Challenges & Solutions
3.2.4 Viral Vector Production, Analytics: Challenges & Solutions
3.3 Penetration & Growth Prospect Mapping for Vector Type, 2019
3.4 Penetration & Growth Prospect Mapping for Prominent Industry Players, 2019
3.5 Manufacturer's Landscape
3.6 Viral Vector & Plasmid DNA Manufacturing Market-SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
3.7 Industry Analysis - Porter's
Chapter 4 Viral Vector Production Capacity Mapping Analysis
4.1 CMOs Capacity for Viral Vector Manufacturing
4.2 In-house Manufacturers Capacity for Viral Vector Manufacturing
4.3 Cleanroom Suites Facilities: Leading Viral Vector Manufacturers
4.4 Prominent Players: Location Mapping & existing Capacities
4.5 AAV and LV vector candidate developing organizations
4.6 CMO Mammalian Cell Culture Capacity of Key Players in Viral Vector/Gene/Cell Therapy Space: Key Statistics
4.7 Mammalian cell lines: Capacity & Investments
4.7.1 Small Scale Companies: Mammalian Cell Culture Capacities
4.7.2 Medium scale companies: Mammalian cell culture capacities
4.7.3 Large scale companies: Mammalian cell culture capacities
4.8 List of Companies with Portfolio Comprising Vector-based Therapeutic Candidates
4.9 List of Vector Manufacturers
Chapter 5 Viral Vector Production: Costs
5.1 Cost Models
5.1.1 Campaign model
5.1.2 Day rate model
5.1.3 Hybrid model
Chapter 6 Viral Vector Production & Yield Analysis
6.1 Production Yields: Biomarin, Spark Therapeutics & Solid Biosciences
6.2 Various Modes of Vector Production to increase & achieve Target Doses
6.2.1 Adenoviral vectors
6.2.2 ?- retroviral (MLV - murineleukemia virus) vectors
6.2.3 Lentiviral vectors
6.2.4 AAV vectors
6.2.5 rAAV vectors
6.2.5.1 rAAV Production : Challenges & Solutions
6.3 Total vector quantity produced per day and yield volume using different cell culture systems
6.4 Measures undertaken to optimize manufacturing of viral vectors for cell and gene therapy
6.5 Analysis of large- and small-scale production of viral vectors based on batch size
6.5.1 Small-scale/laboratory-scale cell culture systems
6.5.2 Large-scale cell culture systems
6.6 Common Practices for Small-Scale (10-50L) Adenovirus Vector Manufacturing
Chapter 7 Viral Vector Manufacturing: Process Economic Considerations & Challenges
7.1 Technological Advances in Manufacturing
7.1.1 Stable Producer Cell Lines
7.1.2 Transient production
7.1.3 Lentiviral vector production process
7.1.3.1 Developments in LentiVector platform
7.2 CoGs Analysis of the Baseline Process
7.2.1 Raw Material
7.2.2 Labor costs
7.2.3 Process costs
7.3 Regulatory Expectations
7.4 Approaches for Viral Vector Supply Gene Therapy
7.4.1 Gene Therapy Manufacturing Facilities: Trends & Types
7.4.2 Gene Therapy Road Map: Key External Trends
Chapter 8 Viral Vector Manufacturing Market: Strategic Alliances
8.1 Is The Time Right To Invest In Gene Therapy Sector?
8.2 Strategic Approaches for Market Scale-Up
8.3 Partnership Models
8.3.1 Acquisition
8.3.2 Minority interest (ownership)
8.3.3 Joint venture
8.3.4 Alliance
8.3.5 Franchise
8.4 Collaborations in Viral Vector Manufacturing Market
8.4.1 Breakthrough Growth: Lonza, Oxford BioMedica & Others
Chapter 9 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Vector Type Estimates & Trend Analysis
9.1 Viral Vector & Plasmid DNA Manufacturing Market: Vector Type Movement Analysis
9.2 Adenovirus
9.2.1 Global adenovirus market, 2016 - 2027 (USD Million)
9.3 Retrovirus
9.3.1 Global retrovirus market, 2016 - 2027 (USD Million)
9.4 Plasmid DNA
9.4.1 Global plasmid DNA market, 2016 - 2027 (USD Million)
9.5 AAV
9.5.1 Global AAV market, 2016 - 2027 (USD Million)
9.6 Lentivirus
9.6.1 Global lentivirus market, 2016 - 2027 (USD Million)
9.7 Other Vectors
9.7.1 Global other vectors market, 2016 - 2027 (USD Million)
Chapter 10 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Workflow Estimates & Trend Analysis
10.1 Viral Vector & Plasmid DNA Manufacturing Market: Workflow Movement Analysis
10.2 Upstream Manufacturing
10.2.1 Global upstream manufacturing market, 2016 - 2027 (USD Million)
10.2.2 Vector amplification & expansion
10.2.2.1 Global vector amplification & expansion market, 2016 - 2027 (USD Million)
10.2.3 Vector recovery/harvesting
10.2.3.1 Global vector recovery/harvesting market, 2016 - 2027 (USD Million)
10.3 Downstream Manufacturing
10.3.1 Global downstream manufacturing market, 2016 - 2027 (USD Million)
10.3.2 Purification
10.3.2.1 Global purification market, 2016 - 2027 (USD Million)
10.3.3 Fill Finish
10.3.3.1 Global fill finish market, 2016 - 2027 (USD Million)
Chapter 11 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Application Estimates & Trend Analysis
11.1 Viral Vector & Plasmid DNA Manufacturing Market: Application Movement Analysis
11.2 Antisense & RNAi Therapy
11.2.1 Market for antisense, & RNAi therapy, 2016 - 2027 (USD Million)
11.3 Cell Therapy
11.3.1 Market for cell therapy, 2016 - 2027 (USD Million)
11.4 Gene Therapy
11.4.1 Market for gene therapy, 2016 - 2027 (USD Million)
11.5 Vaccinology
11.5.1 Market for vaccinology, 2016 - 2027 (USD Million)
Chapter 12 Viral Vector & Plasmid DNA Manufacturing Market Categorization: End-use Estimates & Trend Analysis
12.1 Viral Vector & Plasmid DNA Manufacturing Market: End-use Movement Analysis
12.2 Pharmaceutical and Biopharmaceutical Companies
12.2.1 Market for pharmaceutical and biopharmaceutical companies, 2016 - 2027 (USD Million)
12.3 Research Institutes
12.3.1 Market for research institutes, 2016 - 2027 (USD Million)
Chapter 13 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Disease Estimates & Trend Analysis
13.1 Viral Vector & Plasmid DNA Manufacturing Market: Disease Movement Analysis
13.2 Cancer
13.2.1 Market for cancer, 2016 - 2027 (USD Million)
13.3 Genetic Disorders
13.3.1 Market for genetic disorders, 2016 - 2027 (USD Million)
13.4 Infectious Diseases
13.4.1 Market for infectious diseases, 2016 - 2027 (USD Million)
13.5 Others
13.5.1 Market for other diseases, 2016 - 2027 (USD Million)
Chapter 14 Market Categorization: Regional Estimates & Trend Analysis, by Product
14.1 Viral Vector & Plasmid DNA Manufacturing Market Share By Regional, 2019 & 2027
14.2 North America
14.2.1 North America viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
14.2.2 U.S.
14.2.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
14.2.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
14.2.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
14.2.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
14.2.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
14.2.3 Canada
14.2.3.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
14.2.3.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
14.2.3.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
14.2.3.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
14.2.3.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
14.3 Europe
14.3.1 Europe viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
14.3.2 Germany
14.3.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
14.3.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
14.3.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
14.3.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
14.3.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
14.3.3 U.K.
14.3.3.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
14.3.3.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
14.3.3.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
14.3.3.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
14.3.3.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
14.4 Asia Pacific
14.4.1 Asia Pacific viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
14.4.2 Japan
14.4.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
14.4.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
14.4.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
14.4.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
14.4.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
14.4.3 China
14.4.3.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
14.4.3.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
14.4.3.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
14.4.3.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
14.4.3.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
14.5 Latin America
14.5.1 Latin America viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
14.5.2 Brazil
14.5.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
14.5.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
14.5.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
14.5.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
14.5.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
14.6 MEA
14.6.1 MEA viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
14.6.2 South Africa
14.6.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
14.6.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
14.6.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
14.6.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
14.6.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
Chapter 15 Competitive Landscape
15.1 Strategy Framework
15.2 Market Participation Categorization
15.3 Company Profiles: Contract Manufacturing Organizations (CMOs)
15.3.1 Merck KGaA
15.3.1.1 Company overview
15.3.1.1.1 Sigma-Aldrich Co. LLC
15.3.1.2 Financial performance
15.3.1.3 Product benchmarking
15.3.1.4 SWOT analysis
15.3.1.5 Operational capacity
15.3.1.6 Strategic initiatives
15.3.2 Lonza
15.3.2.1 Company overview
15.3.2.2 Financial performance
15.3.2.3 Product benchmarking
15.3.2.4 SWOT analysis
15.3.2.5 Operational capacity
15.3.2.6 Strategic initiatives
15.3.3 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
15.3.3.1 Company overview
15.3.3.2 Financial performance
15.3.3.3 Product benchmarking
15.3.3.4 SWOT analysis
15.3.3.5 Operational capacity
15.3.3.6 Strategic initiatives
15.3.4 Cobra Biologics Ltd.
15.3.4.1 Company overview
15.3.4.2 Financial performance
15.3.4.3 Product benchmarking
15.3.4.4 SWOT analysis
15.3.4.5 Operational capacity
15.3.4.6 Strategic initiatives
15.3.5 Brammer Bio
15.3.5.1 Company overview
15.3.5.2 Financial performance
15.3.5.3 Product benchmarking
15.3.5.4 SWOT analysis
15.3.5.5 Operational capacity
15.3.5.6 Strategic initiatives
15.3.6 Waisman Biomanufacturing
15.3.6.1 Company overview
15.3.6.2 Financial performance
15.3.6.3 Product benchmarking
15.3.6.4 SWOT analysis
15.3.6.5 Operational capacity
15.3.6.6 Strategic initiatives
15.3.7 Genezen
15.3.7.1 Company overview
15.3.7.2 Product benchmarking
15.3.7.3 SWOT analysis
15.3.7.4 Operational capacity
15.3.7.5 Strategic initiatives
15.3.8 YPOSKESI
15.3.8.1 Company overview
15.3.8.2 Financial performance
15.3.8.3 Product benchmarking
15.3.8.4 SWOT analysis
15.3.8.5 Operational capacity
15.3.8.6 Strategic initiatives
15.3.9 Advanced BioScience Laboratories, Inc. (ABL, Inc.)
15.3.9.1 Company overview
15.3.9.2 Financial performance
15.3.9.3 Product benchmarking
15.3.9.4 SWOT analysis
15.3.9.5 Operational capacity
15.3.9.6 Strategic initiatives
15.3.10 Novasep Holding S.A.S
15.3.10.1 Company overview
15.3.10.2 Product benchmarking
15.3.10.3 SWOT analysis
15.3.10.4 Operational capacity
15.3.10.5 Strategic initiatives
15.3.11 ATVIO Biotech Ltd
15.3.11.1 Company overview
15.3.11.2 Financial performance
15.3.11.3 Product benchmarking
15.3.11.4 SWOT analysis
15.3.11.5 Operational capacity
15.3.11.6 Strategic initiatives
15.3.12 Vigene Biosciences, Inc.
15.3.12.1 Company overview
15.3.12.2 Financial performance
15.3.12.3 Product benchmarking
15.3.12.4 SWOT analysis
15.3.12.5 Operational capacity
15.3.12.6 Strategic initiatives
15.3.13 General Electric Company (GE Healthcare)
15.3.13.1 Company overview
15.3.13.2 Financial performance
15.3.13.3 Product benchmarking
15.3.13.4 SWOT analysis
15.3.13.5 Operational capacity
15.3.13.6 Strategic initiatives
15.3.14 CEVEC Pharmaceuticals GmbH
15.3.14.1 Company overview
15.3.14.2 Financial performance
15.3.14.3 Product benchmarking
15.3.14.4 SWOT analysis
15.3.14.5 Operational capacity
15.3.14.6 Strategic initiatives
15.3.15 Batavia Biosciences B.V.
15.3.15.1 Company overview
15.3.15.2 Financial performance
15.3.15.3 Product benchmarking
15.3.15.4 SWOT analysis
15.3.15.5 Operational capacity
15.3.15.6 Strategic initiatives
15.3.16 Biovian Oy
15.3.16.1 Company overview
15.3.16.2 Financial performance
15.3.16.3 Product benchmarking
15.3.16.4 SWOT analysis
15.3.16.5 Operational capacity
15.3.16.6 Strategic initiatives
15.3.17 Wuxi AppTec Co., Ltd.
15.3.17.1 Company overview
15.3.17.2 Financial performance
15.3.17.3 Product benchmarking
15.3.17.4 SWOT analysis
15.3.17.5 Operational capacity
15.3.17.6 Strategic initiatives
15.3.18 VGXI, Inc.
15.3.18.1 Company overview
15.3.18.2 Financial performance
15.3.18.3 Product benchmarking
15.3.18.4 SWOT analysis
15.3.18.5 Operational capacity
15.3.18.6 Strategic initiatives
15.3.19 Paragon Bioservices, Inc
15.3.19.1 Company overview
15.3.19.2 Financial performance
15.3.19.3 Product benchmarking
15.3.19.4 SWOT analysis
15.3.19.5 Operational capacity
15.3.19.6 Strategic initiatives
15.3.20 Miltenyi Biotec GmbH
15.3.20.1 Company overview
15.3.20.2 Lentigen Technology, Inc.
15.3.20.3 Financial performance
15.3.20.4 Product benchmarking
15.3.20.5 SWOT analysis
15.3.20.6 Operational capacity
15.3.20.7 Strategic initiatives
15.3.21 SIRION Biotech GmbH
15.3.21.1 Company overview
15.3.21.2 Financial performance
15.3.21.3 Product benchmarking
15.3.21.4 SWOT analysis
15.3.21.5 Operational capacity
15.3.21.6 Strategic initiatives
15.3.22 Virovek Incorporation
15.3.22.1 Company overview
15.3.22.2 Financial performance
15.3.22.3 Product benchmarking
15.3.22.4 SWOT analysis
15.3.22.5 Operational capacity
15.3.22.6 Strategic initiatives
15.3.23 BioNTech IMFS GmbH
15.3.23.1 Company overview
15.3.23.2 Financial performance
15.3.23.3 Product benchmarking
15.3.23.4 SWOT analysis
15.3.23.5 Operational capacity
15.3.24 VIVEbiotech S.L.
15.3.24.1 Company overview
15.3.24.2 Financial performance
15.3.24.3 Product benchmarking
15.3.24.4 SWOT analysis
15.3.24.5 Operational capacity
15.3.24.6 Strategic initiatives
15.3.25 Creative Biogene
15.3.25.1 Company overview
15.3.25.2 Product benchmarking
15.3.25.3 SWOT analysis
15.3.26 Vibalogics GmbH
15.3.26.1 Company overview
15.3.26.2 Product benchmarking
15.3.26.3 SWOT analysis
15.3.26.4 Operational capacity
15.3.26.5 Strategic initiatives
15.4 Company Profiles: In-house Manufacturers
15.4.1 Cell and Gene Therapy Catapult
15.4.1.1 Company overview
15.4.1.2 Product benchmarking
15.4.1.3 SWOT analysis
15.4.1.4 Operational capacity
15.4.1.5 Strategic initiatives
15.4.2 BlueBird Bio
15.4.2.1 Company overview
15.4.2.2 Financial performance
15.4.2.3 Product benchmarking
15.4.2.4 SWOT analysis
15.4.2.5 Operational capacity
15.4.2.6 Strategic initiatives
15.4.3 Addgene, Inc.
15.4.3.1 Company overview
15.4.3.2 Financial performance
15.4.3.3 Product benchmarking
15.4.3.4 SWOT analysis
15.4.3.5 Operational capacity
15.4.3.6 Strategic initiatives
15.4.4 Aldevron, L.L.C.
15.4.4.1 Company overview
15.4.4.2 Financial performance
15.4.4.3 Product benchmarking
15.4.4.4 SWOT analysis
15.4.4.5 Operational capacity
15.4.4.6 Strategic initiatives
15.4.5 Audentes Therapeutics
15.4.5.1 Company overview
15.4.5.2 Financial performance
15.4.5.3 Product benchmarking
15.4.5.4 SWOT analysis
15.4.5.5 Operational capacity
15.4.5.6 Strategic initiatives
15.4.6 BioMarin Pharmaceutical
15.4.6.1 Company overview
15.4.6.2 Financial performance
15.4.6.3 Product benchmarking
15.4.6.4 SWOT analysis
15.4.6.5 Operational capacity
15.4.6.6 Strategic initiatives
List of Tables TABLE 1 Location Mapping TABLE 2 Production yields of rAAV vectors using different production systems TABLE 3 Large-scale production of MLV vectors for clinical applications TABLE 4 Overview of costs involved in cell therapy development TABLE 5 Common raw/starting materials for viral vector manufacturing TABLE 6 Sensitivity of baseline process to failure rates during cell therapy production TABLE 7 Approved cell therapy products TABLE 8 Approved gene therapy products TABLE 9 Clinical trials in cancer gene therapy TABLE 10 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million) TABLE 11 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 12 North America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 13 North America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 14 North America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million) TABLE 15 North America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million) TABLE 16 North America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million) TABLE 17 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million) TABLE 18 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 19 U.S. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 20 U.S. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 21 U.S. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million) TABLE 22 U.S. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million) TABLE 23 U.S. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million) TABLE 24 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million) TABLE 25 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 26 Canada viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 27 Canada upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 28 Canada upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million) TABLE 29 Canada upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million) TABLE 30 Canada upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million) TABLE 31 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million) TABLE 32 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 33 Europe viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 34 Europe upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 35 Europe upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million) TABLE 36 Europe upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million) TABLE 37 Europe upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million) TABLE 38 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million) TABLE 39 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 40 Germany viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 41 Germany upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 42 Germany upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million) TABLE 43 Germany upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million) TABLE 44 Germany upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million) TABLE 44 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million) TABLE 45 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 46 U.K. viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 47 U.K. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 48 U.K. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million) TABLE 49 U.K. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million) TABLE 50 U.K. upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million) TABLE 51 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million) TABLE 52 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 53 Asia Pacific viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 54 Asia Pacific upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 55 Asia Pacific upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million) TABLE 56 Asia Pacific upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million) TABLE 57 Asia Pacific upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million) TABLE 58 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million) TABLE 59 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 60 Japan viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 61 Japan upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 62 Japan upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million) TABLE 63 Japan upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million) TABLE 64 Japan upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million) TABLE 65 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million) TABLE 66 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 67 China viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 68 China upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 69 China upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million) TABLE 70 China upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million) TABLE 71 China upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million) TABLE 72 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million) TABLE 73 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 74 Latin America viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 75 Latin America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 76 Latin America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million) TABLE 77 Latin America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million) TABLE 78 Latin America upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million) TABLE 79 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million) TABLE 80 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 81 Brazil viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 82 Brazil upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 83 Brazil upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million) TABLE 84 Brazil upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million) TABLE 85 Brazil upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million) TABLE 86 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million) TABLE 87 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 88 MEA viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 89 MEA upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 90 MEA upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million) TABLE 91 MEA upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million) TABLE 92 MEA upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million) TABLE 93 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by vector type, 2016 - 2027 (USD Million) TABLE 94 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 95 South Africa viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 96 South Africa upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by workflow, 2016 - 2027 (USD Million) TABLE 97 South Africa upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by application, 2016 - 2027 (USD Million) TABLE 98 South Africa upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by end-use, 2016 - 2027 (USD Million) TABLE 99 South Africa upstream viral vector & plasmid DNA manufacturing market estimates & forecasts, by disease, 2016 - 2027 (USD Million)
List of Figures FIG. 1 Market summary FIG. 2 Market research process FIG. 3 Information procurement FIG. 4 Primary research pattern FIG. 5 Market research approaches FIG. 6 Value chain-based sizing & forecasting FIG. 7 QFD modeling for market share assessment FIG. 8 Market trends & outlook FIG. 9 Market segmentation & scope FIG. 10 Market driver relevance analysis (Current & future impact) FIG. 11 Gene therapies in development (at all stages) per disease group, 2016 FIG. 12 Pipeline analysis for viral vector manufacturing FIG. 13 Pipeline analysis for viral vector manufacturing FIG. 14 Pipeline analysis for viral vector manufacturing FIG. 15 Recent and expected upcoming US/EU approvals for gene transfer-mediated programs FIG. 16 Market restraint relevance analysis (Current & future impact) FIG. 17 Various ethical questions raised by gene therapy FIG. 18 Recent and ongoing manufacturing capacity expansions for viral vector and large-scale cell therapies, as of 2017 FIG. 19 Plasmid Production: Challenges & Solutions FIG. 20 Host Cell Production & Banking Needs FIG. 21 Viral Vector Production, F&F: Challenges & Solutions FIG. 22 Viral Vector Production, Analytics: Challenges & Solutions FIG. 23 Penetration & growth prospect mapping for vector type, 2019 FIG. 24 Penetration & growth prospect mapping for prominent industry players, 2019 FIG. 25 Viral Vector Manufacturing Landscape FIG. 26 SWOT analysis, by factor (Political & legal, economic, and technological) FIG. 27 Porter's Five Forces Analysis FIG. 28 Capacity Mapping: CMOs in Viral Vector Manufacturing Market FIG. 29 Capacity Mapping: In-house Manufacturers in Viral Vector Manufacturing Market FIG. 30 Cleanroom Suites in Viral Vector Manufacturing Market FIG. 31 AAV and LV vector candidate developing organizations FIG. 32 Historical & estimated CMO mammalian cell culture capacity of key players in viral vector/gene/cell therapy space FIG. 33 Investments by key players to expand their production capacity for mammalian cells FIG. 34 Companies with small scale bioreactors for mammalian cell culture FIG. 35 Companies with medium scale bioreactors for mammalian cell culture FIG. 36 Companies with large scale bioreactors for mammalian cell culture FIG. 37 List of companies with portfolio comprising vector-based therapeutic candidates FIG. 38 List of vector manufacturers FIG. 39 Comparison of costs estimated by campaign, day rate, and hybrid models FIG. 40 Campaign model for viral vector production FIG. 41 Day rate model for viral vector production FIG. 42 Hybrid model for viral vector production FIG. 43 Company-wise: Vector yields FIG. 44 Prevailing Technologies for AAV Production FIG. 45 rAAV Production : Challenges & Solutions FIG. 46 iCELLis systems: Productivities FIG. 47 Small- & large-scale cell culture systems for production of viral vectors FIG. 48 Process flow diagram for common practices for small-scale (10-50 L) adenoviral vector purification FIG. 49 Comparison of viral titers obtained from different LVV production methods FIG. 50 Lentiviral Vector Clinical Trials, By year and Phase FIG. 51 Breakdown of CoGs per process for cell therapy manufacture FIG. 52 Progression of cGMP compliance at different product development stages FIG. 53 Standardization & Regulatory Challenges FIG. 54 Gene Therapy Manufacturing Facilities: Trends & Types FIG. 55 Gene Therapy Road Map: Key External Trends FIG. 56 Strategic Approaches for Market Scale-Up FIG. 57 Viral vector & plasmid DNA manufacturing market: Vector type outlook key takeaways FIG. 58 Global viral vector & plasmid DNA manufacturing market: Vector type movement analysis FIG. 59 Global adenovirus market, 2016 - 2027 (USD Million) FIG. 60 Global retrovirus market, 2016 - 2027 (USD Million) FIG. 61 Global plasmid DNA market, 2016 - 2027 (USD Million) FIG. 62 Global AAV market, 2016 - 2027 (USD Million) FIG. 63 Global lentivirus market, 2016 - 2027 (USD Million) FIG. 64 Global other vectors market, 2016 - 2027 (USD Million) FIG. 65 Viral vector & plasmid DNA manufacturing market: Workflow outlook key takeaways FIG. 66 Global viral vector & plasmid DNA manufacturing market: Workflow movement analysis FIG. 67 Global upstream manufacturing market, 2016 - 2027 (USD Million) FIG. 68 Global vector amplification & expansion market, 2016 - 2027 (USD Million) FIG. 69 Global vector recovery/harvesting market, 2016 - 2027 (USD Million) FIG. 70 Global downstream manufacturing market, 2016 - 2027 (USD Million) FIG. 71 Global purification market, 2016 - 2027 (USD Million) FIG. 72 Global fill finish market, 2016 - 2027 (USD Million) FIG. 73 Viral vector & plasmid DNA manufacturing market: Application outlook key takeaways FIG. 74 Global viral vector & plasmid DNA manufacturing market: Application movement analysis FIG. 75 Global viral vector & plasmid DNA manufacturing market for antisense, & RNAi therapy, 2016 - 2027 (USD Million) FIG. 76 Global viral vector & plasmid DNA manufacturing market for cell therapy, 2016 - 2027 (USD Million) FIG. 77 Global viral vector & plasmid DNA manufacturing market for gene therapy, 2016 - 2027 (USD Million) FIG. 78 Strengths and weaknesses of viral vector vaccines FIG. 79 Global viral vector & plasmid DNA manufacturing market for vaccinology, 2016 - 2027 (USD Million) FIG. 80 Viral vector & plasmid DNA manufacturing market: End-use outlook key takeaways FIG. 81 Global viral vector & plasmid DNA manufacturing market: End-use movement analysis FIG. 82 Global viral vector & plasmid DNA manufacturing market for pharmaceutical and biopharmaceutical companies, 2016 - 2027 (USD Million) FIG. 83 Global viral vector & plasmid DNA manufacturing market for research institutes, 2016 - 2027 (USD Million) FIG. 84 Viral vector & plasmid DNA manufacturing market: Disease outlook key takeaways FIG. 85 Global viral vector & plasmid DNA manufacturing market: Disease movement analysis FIG. 86 Global viral vector & plasmid DNA manufacturing market for cancer, 2016 - 2027 (USD Million) FIG. 87 Global viral vector & plasmid DNA manufacturing market for genetic disorders, 2016 - 2027 (USD Million) FIG. 88 Global viral vector & plasmid DNA manufacturing market for infectious diseases, 2016 - 2027 (USD Million) FIG. 89 Global viral vector & plasmid DNA manufacturing market for other diseases, 2016 - 2027 (USD Million) FIG. 90 Regional market place: Key takeaway FIG. 91 Viral vector & plasmid DNA manufacturing market: Regional outlook, 2019 & 2027 FIG. 92 North America viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million) FIG. 93 U.S. viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million) FIG. 94 Canada viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million) FIG. 95 Europe viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million) FIG. 96 Germany viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million) FIG. 97 U.K. viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million) FIG. 98 Asia Pacific viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million) FIG. 99 Japan viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million) FIG. 100 China viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million) FIG. 101 Latin America viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million) FIG. 102 Brazil viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million) FIG. 103 MEA viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million) FIG. 104 South Africa viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million) FIG. 105 Strategy framework FIG. 106 Market participation categorization FIG. 107 SWOT analysis: Merck FIG. 108 SWOT analysis: Lonza FIG. 109 SWOT analysis: FUJIFILM FIG. 110 SWOT analysis: Cobra Biologics FIG. 111 SWOT analysis: Brammer Bio FIG. 112 SWOT analysis: Waisman Biomanufacturing FIG. 113 SWOT analysis: Genezen FIG. 114 SWOT analysis: YPOSKESI FIG. 115 SWOT analysis: ABL FIG. 116 SWOT analysis: Novasep FIG. 117 SWOT analysis: ATVIO FIG. 118 SWOT analysis: Vigene Biosciences FIG. 119 SWOT analysis: GE Healthcare FIG. 120 SWOT analysis: CEVEC FIG. 121 SWOT analysis: Batavia Biosciences FIG. 122 SWOT analysis: Biovian FIG. 123 SWOT analysis: WuXi AppTec FIG. 124 SWOT analysis: VGXI FIG. 125 SWOT analysis: Paragon Bioservices, Inc. FIG. 126 SWOT analysis: Lentigen Technology FIG. 127 SWOT analysis: Sirion-Biotech FIG. 128 SWOT analysis: VIROVEK FIG. 129 SWOT analysis: BioNTech FIG. 130 SWOT analysis: VIVE biotech FIG. 131 SWOT analysis: Creative Biogene FIG. 132 SWOT analysis: Vibalogics FIG. 133 SWOT analysis: Cell and Gene Therapy Catapult FIG. 134 SWOT analysis: BlueBird Bio FIG. 135 SWOT analysis: Addgene FIG. 136 SWOT analysis: Aldevron FIG. 137 SWOT analysis: Audentes FIG. 138 SWOT analysis: BioMarin Pharmaceutical
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
